Added to YB: 2026-08-27
Pitch date: 2026-08-25
MEDXF [bullish]
Medexus Pharmaceuticals Inc.
+1.97%
current return
Author Info
No bio for this author
Company Info
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases.
Market Cap
CAD 117.7M
Pitch Price
CAD 5.08
Price Target
N/A
Dividend
N/A
EV/EBITDA
8.24
P/E
-50.88
EV/Sales
1.34
Sector
Pharmaceuticals
Category
growth
Weekly #18: Most Interesting D-Sheets from the Past Week (Aug 18 – Aug 24, 2026) - MEDXF — Medexus Pharmaceuticals Inc. - Strong Signal
MEDXF (earnings): FQ1'27: rev +16.3% to $28.6M, op inc +133% to $2.1M, adj EBITDA +38% to $4.7M. GRAFAPEX (treosulfan) inflected profitable — $4.9M product rev vs $3.2M spend, 75 institutions ordering/54 repeating, minimal discounting, July 2nd-best month ever, ~85% adult adoption. Mgmt frames $100-175M long-term GRAFAPEX opportunity (29-42% share) vs FY target $30-32M — big upside to run rate. Catalyst: fall Health Canada UM171 discussion could pull forward expedited path vs 2028-31. Mkt cap ~$116M. Risks: negative OCF, rising net debt, legacy erosion (Rupall generic, Glioland loss); thesis needs acceleration to persist.
Read full article (1 min)